Except for one patient (No. 1) with a HER2+ tumor who received palbociclib plus TDM-1, all other patients received palbociclib plus endocrine therapy, including eight that received palbociclib plus fulvestrant, and seven received palbociclib plus letrozole. Here, ERBB2 is linked to neoplasm.